



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: <b>A61K 38/00, 31/70, 48/00</b>		A1	(11) International Publication Number: <b>WO 95/09002</b> (43) International Publication Date: <b>6 April 1995 (06.04.95)</b>
<b>(21) International Application Number:</b> PCT/US94/11108 <b>(22) International Filing Date:</b> 30 September 1994 (30.09.94) <b>(30) Priority Data:</b> 129,381 30 September 1993 (30.09.93) US		<b>(81) Designated States:</b> AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).  <b>Published</b> <i>With international search report.</i>	
<b>(71) Applicant:</b> UNIVERSITY OF PENNSYLVANIA [US/US]; Center for Technology Transfer, Suite 300, 3700 Market Street, Philadelphia, PA 19104-3147 (US).  <b>(72) Inventors:</b> SCHREIBER, Alan, D.; 821 Westview Street, Philadelphia, PA 19119 (US). PARK, Jong-Gu; 6813 Drexelbrook Drive, Drexel Hill, PA 19026 (US).  <b>(74) Agent:</b> WILSON, Mary, J.; Nixon & Vanderhye, 8th floor, 1100 North Glebe Road, Arlington, VA 22201-4714 (US).			

(54) Title: METHODS OF INHIBITING PHAGOCYTOSIS

## (57) Abstract

The present invention relates, in general, to methods of treating diseases resulting from interactions between immune complexes and Fc receptors. In particular, the present invention relates to methods of modulating the clearance of antibody-coated cells from the circulation by inhibiting phagocytosis and to methods of modulating the interaction of immune complexes with tissue Fc receptors. Further, the invention relates to methods of modulating the activation of immunological processes mediated by Fc receptor activation resulting from antibody-antigen/receptor interaction.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**METHODS OF INHIBITING PHAGOCYTOSIS**

This is a continuation-in-part of Application No. 08/129,381, filed September 30, 1993, the contents of which are incorporated herein by reference.

5

**TECHNICAL FIELD**

The present invention relates, in general, to methods of treating diseases resulting from interactions between immune complexes and Fc receptors. In particular, the present invention relates to methods of modulating the clearance of antibody-coated cells, viruses, or soluble antigens by inhibiting phagocytosis, and to methods of modulating the interaction of immune complexes with cellular or tissue Fc receptors. The invention also relates to the modulation of those immune reactions for which the reaction of antigen-antibody complexes with Fc receptors is an important initiating step.

10

15

**BACKGROUND OF THE INVENTION**

20

Certain immunological disorders are characterized by a disturbance in the expression of monocyte or macrophage Fc (IgG) receptors. An increase in the number of Fc receptors can result from an increase in the level of Fc receptor mediators such as gamma interferon or infection or the release of bacterial products. A decrease in the number of Fc receptors

25

that can bind IgG can result not only from a reduction in the actual number of functional receptors but also from the saturation of Fc receptors by immune complexes. In certain autoimmune diseases, such as 5 systemic lupus erythematosus, levels of circulating immune complexes can be high and thus receptor saturation can occur.

In autoimmune diseases, the body's mechanisms for distinguishing between itself and foreign invaders 10 malfunction. Typically, the body begins to make antibodies to certain parts of itself; these antibodies trigger the immune system which then destroys the tissue identified by the abnormal antibodies.

Autoimmune diseases have varied focal points of 15 attack. The autoimmune hemolytic anemias represent a group of disorders in which individuals produce antibodies to one or more of their own erythrocyte membrane antigens. Coating of erythrocytes by the abnormal antibodies is followed by their clearance from 20 the circulation by splenic macrophages and subsequent destruction in the spleen. Representative diseases in this class are immune hemolytic anemia, immune thrombocytopenic purpura and autoimmune neutropenia. Another type of autoimmune disease is the type 25 represented by systemic lupus erythematosus and rheumatoid arthritis. In these diseases, chronic inflammation is present in the joints, tendons, kidneys, lung, heart and other organs. In rheumatoid arthritis, for example, breakdown of joint cartilage 30 into the synovial fluid of the joint is present in

later stages of the disease. In systemic lupus erythematosus, however, cartilage or bone degradation is not usually found. Systemic lupus erythematosus and rheumatoid arthritis are often present in conjunction with other types of autoimmune disease. In systemic lupus erythematosus and rheumatoid arthritis, tissue destruction is associated with the presence of IgG-containing complexes in the circulation. It is believed that recognition of these complexes in tissues by cells having Fc receptors initiates or increases tissue destruction by macrophages and possibly other cells such as polymorphonuclear leukocytes in these tissues. Reaction with these Fc receptors initiates a range of immune-associated reactions that may harm body tissues in proximity to these Fc receptor bearing cells.

Diseases that involve the interaction of IgG-containing immune complexes with macrophage Fc receptors are often treated with corticosteroids, or immunosuppressants. These treatments can have diverse and serious side effects. The present invention offers alternative treatment approaches that can be used alone or in combination with more conventional drug therapies.

25

#### SUMMARY OF THE INVENTION

It is a general object of the invention to provide a method of modulating the clearance of antibody-coated

cells or immune complexes, for example, by inhibiting the phagocytic potential of cells bearing Fc receptors.

It is a specific object of the invention to provide methods of regulating the clearance of immune complexes from a mammal. In addition, it is a specific object of the invention to provide a method of inhibiting the binding of immune complexes to membrane-bound Fc receptors (and/or inhibiting ingestion of such complexes), thereby inhibiting the sequelae of undesirable tissue damage.

It is a further object of the invention to provide constructs and compounds suitable for use in the above-described methods.

In one embodiment, the present invention relates to a method of preventing the phagocytosis of immune complexes (eg IgG-containing immune complexes) and/or the release of intracellular biologically active products by cells interacting with immune complexes. An example of the present method comprises introducing into phagocytic cells of the mammal that are in contact with the immune complexes (eg, IgG-containing immune complexes) an inhibitor of a kinase endogenous to the cells that activates an Fc receptor present at the membrane of the cells.

In another embodiment, the present invention relates to a method of preventing the clearance of immune complexes (eg, IgG-containing immune complexes) from a mammal that comprises introducing into hematopoietic cells (eg phagocytic cells) of the mammal that are in contact with the immune complexes a

molecule that specifically prevents Fc receptor expression at the membrane of the cells.

In a further embodiment, the present invention relates to a method of inhibiting the binding of immune complexes (eg, IgG-containing immune complexes) present in a mammal to membrane-bound Fc receptors. The method comprises introducing into the mammal a soluble Fc receptor that competes with the membrane-bound Fc receptor for binding to the immune complex. The introduction is effected under conditions such that binding of the immune complex to the membrane-bound Fc receptor is inhibited.

In yet another embodiment, the present invention relates to a method of inhibiting the phagocytic potential of a mammalian cell bearing an Fc receptor. The method comprises introducing into the cell a construct comprising, in the 5'-3' direction of transcription:

- i) a promoter functional in the cell,
- ii) a segment of double-stranded DNA the transcribed strand of which comprises a sequence complementary to endogenous mRNA encoding the Fc receptor, and
- iii) a termination sequence functional in the cell. The construct is introduced under conditions such that the complementary strand is transcribed and binds to the endogenous mRNA thereby reducing expression of the Fc receptor and inhibiting the phagocytic potential of the cell.

Further objects and advantages of the present invention will be clear from the description that follows. It will be appreciated that the disclosure should be read in light of the teachings available in the art relating to the isolation and cloning of the three classes of Fc $\gamma$  receptors (Fc $\gamma$ RI, Fc $\gamma$ RII and Fc $\gamma$ RIII) (see, for example, Allen and Seed, *Science* 243:378 (1989); Hibbs et al, *Proc. Natl. Acad. Sci. USA* 85:2240 (1988); *J. Exp. Med.* 166:1668 (1987); van de Winkle et al, *FASEB J.*, 5:A964 (1991); Brooks et al, *J. Exp. Med.* 170:369 (1989); Stuart et al, *EMBO J.* 8:3657 (1989); Qui et al, *Science* 248:732 (1990); Simmons and Seed, *Nature* 333:568 (1988); see also, Schreiber et al, *Clin. Immunol. Immunopath.* 62:S66 (1992).

15

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a schematic representation of Fc $\gamma$ RIIIA  $\gamma$  wild type and mutants. Shown above the schematic diagram of the  $\gamma$  chain are signal sequence (S), external peptides (E), transmembrane domain (TM), and cytoplasmic domain (CY). The expanded area shows an area of the nucleotide sequence of the  $\gamma$  chain containing the conserved motif. In this Figure, the murine  $\gamma$  chain is shown. The conserved amino acids of the gene family of the  $\gamma$  and  $\zeta$  chain genes are denoted by the underline. The N-proximal tyrosine encoded by the TAC codon of the nucleotides 235-237 (Ra et al, *J. Biol. Chem.* 264:15323 (1989)) was conservatively replaced with a phenylalanine encoded by TTC (clones

M1A and M1B). Similarly, the C-proximal tyrosine encoded by TAT (168-270) was replaced with a phenylalanine encoded by TTT (clones M2A and M2B). For the double tyrosine-substitution mutants, both the N- 5 and C-proximal tyrosines were replaced with phenylalanine (clones DMA and DMB). Solid lines of the mutants represent identical sequences to that of the wild type  $\gamma$  gene.

Figures 2A and 2B show binding and phagocytosis of IgG-sensitized RBCs (EA) by transfected COS-1 cells. 10 Binding of EA by transfected COS-1 cells (left panel: A, C, E and G). Phagocytosis of EA by transfected COS-1 cells (right panel; B, D, F, and H). (A) and (B): binding and phagocytosis of COS-1 cells transfected 15 with Fc $\gamma$ RIIIA  $\alpha$  and wild type  $\gamma$ . Three of the phagocytosed RBCs shown with wild type  $\gamma$  are marked by arrows in Figure (B), (C) and (D): transfecants containing  $\alpha$  and  $\gamma$  (M1A). (E) and (F): transfecants containing  $\alpha$  and  $\gamma$  (M2A). (G) and (H): transfecants containing  $\alpha$  and  $\gamma$  (DMA). No phagocytosis of EA is 20 seen in D, F and H. Pictures show images magnified by 1000x.

Figure 3 shows tyrosine phosphorylation of the wild type and mutant  $\gamma$  chains by *in vitro* kinase assay. 25 The  $\gamma$  chain was immunoprecipitated with anti- $\gamma$  antisera from lysates of COS-1 transfecants. *In vitro* phosphorylated samples were run on a 12.5% reducing SDS-PAGE gel. The gel was treated with 1N KOH to

remove phosphoserine and threonine, dried and the autoradiogram was examined after 4 days. lane 1: Sham transfectants with Fc $\gamma$ RIIIA- $\alpha$  and pSVL vector without  $\gamma$  cDNA insert. lanes 2: Fc $\gamma$ RIIIA  $\alpha$  + wild type human  $\gamma$ . lane 3: Fc $\gamma$ RIIIA  $\alpha$  + wild type mouse  $\gamma$ . lane 4: Fc $\gamma$ RIIIA  $\alpha$  + M1A. lane 5: Fc $\gamma$ RIIIA  $\alpha$  + M2A. lane 6: Fc $\gamma$ RIIIA  $\alpha$  + DMA. The phosphorylated  $\gamma$  chains are denoted by an arrow (shown on the lower right side). The arrow with an asterisk (shown on the upper right side) is a specific tyrosine phosphoprotein band at approximately 40 kDa.

Figures 4A-4D are a  $\text{Ca}^{2+}$  mobilization following Fc $\gamma$ RIIIA stimulation. Measurement of  $[\text{Ca}^{2+}]_i$  in individual cells was carried out during crosslinking of Fc $\gamma$ RIIIA. The time points when anti-Fc $\gamma$ RIII mAb, epinephrine (positive control) and calcium ionophore were added are denoted by arrows in each figure. Images were acquired at either 340 or 380 nm excitation (emission = 510 nm). 340/380 ratios were converted to  $[\text{Ca}^{2+}]_i$  based on calibration with Fura-2. The responses of M1A, M2A and DMA transfectants were greatly decreased compared to WT transfectants.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates, at least in part, to methods of modulating the clearance from a mammal (eg, from the circulation of a mammal) of antibody-coated cells. Accordingly, the invention provides methods of treating immunologic disorders, such as autoimmune diseases, characterized by interactions of immune complexes (eg, IgG-containing immune complexes) with Fc receptors (for example, those present on the surface of macrophage), and immune mediated diseases such as asthma. The methods of the invention result in Fc receptor expression and/or function being altered so that phagocytosis of IgG antibody-coated cells is reduced. (One skilled in the art will appreciate that patients suffering from immune complex diseases such as lupus erythematosus and rheumatoid arthritis may benefit from protocols designed so as to increase clearance of circulating immune complexes in the liver and spleen and thereby prevent their deposition in tissues such as the kidney and in the joints. This increase can be effected by stimulating liver and splenic macrophages using protocols for introducing sequences encoding Fc receptors described in the commonly owned application entitled "Methods of Stimulating Phagocytosis" filed concurrently herewith, the entire disclosure of which is incorporated herein by reference.)

More specifically, the invention provides methods of inhibiting Fc receptor function by inhibiting the

phosphorylation of Fc receptor components that is required for phagocytic signal transduction and by introducing into the circulation soluble Fc receptors that compete with the membrane bound receptor for 5 immune complex (eg, IgG-containing immune complex) binding. The invention also provides a method of inhibiting expression of Fc receptors by introducing into receptor-producing cells Fc receptor antisense constructs. The invention also provides methods of 10 degrading Fc receptor RNA using, for example, ribozymes.

Inhibition of Phosphorylation of Fc Receptors:

In one embodiment, the present invention relates to a method of preventing ingestion (eg phagocytosis) 15 of immune complexes (eg IgG-coated cells) by inhibiting phosphorylation of core sequences within the cytoplasmic domain of Fc receptors. Phosphorylation of cytoplasmic residues of Fc $\gamma$ RIIA and the  $\gamma$  subunit of Fc $\gamma$ RIIIA has been shown to be essential for signal 20 transduction events involved in phagocytosis (Indik et al, Trans. Ass. Amer. Phys. 105:214 (1992); Park et al, Clin. Res. 41:324A (1993); Darby et al, Blood 79:352A (1992); Mitchell et al, Clin. Res. 41:189A (1993); Huang et al, J. Biol. Chem. 267:5467 (1992); Hunter et 25 al, Clin. Res. 41:244A (1993); Park et al, J. Clin. Invest. in press (1993)). More specifically, phosphorylation of tyrosine residues present within the motif E-X8-D-X2-Y-X2-L-X12-Y-X2-L, present in the

cytoplasmic domain of Fc $\gamma$ RIIA, and the motif D/E-X2,7-D/E-Y-X2-L-X7-Y-X2-L, present in the cytoplasmic domains of the  $\gamma$  and  $\zeta$  chains of FcRIIIA, is required for phagocytic signal transduction (the numbers following the letter X denote the number of amino acids at that position; X can be any amino acid but X2 within a Y-X2-L is preferably the amino acids present in a Y-X2-L sequence of the cytoplasmic domain of Fc $\gamma$ RIIA or the  $\gamma$  chain of Fc $\gamma$ RIII). It appears that the second Y-X2-L of these core sequences (motifs) is particularly important for phagocytosis. The present invention contemplates the introduction into target cells of an inhibitor of the kinase(s) responsible for phosphorylation. In a specific embodiment, the inhibitor is a peptide that includes a sequence similar to, if not identical to, at least a functional portion of a tyrosine-containing motif (note, for example, the underlined portions of the motifs set forth above) and thus serves as a competitive inhibitor of the kinase(s). As an example, the inhibitor can take the form of an Fc receptor devoid of the extracellular domain or devoid of the extracellular and transmembrane domains. Alternatively, the inhibitor can be structurally distinct from the above motifs, or functional portions thereof, and can inhibit phosphorylation competitively or non-competitively (eg, a mimetic of the active peptide can be used having a structural conformation similar to the binding site of the active peptide). For mast cells, the sequences of the  $\gamma$  chain of Fc $\epsilon$ RI necessary for mediator release

(eg, histamine, cytokines and leukotrienes) can be inhibited using this strategy.

The peptide inhibitor of the invention, or mimetic thereof, can be introduced into target cells directly, 5 for example, using liposomes. (See also approaches described in Science 26:1877 (1993) for administration of peptides modified so as to render them capable of crossing cellular lipid membranes.) Alternatively, a 10 DNA sequence encoding the peptide inhibitor can be introduced using gene therapy protocols so that the peptide is produced intracellularly.

The inhibitor or inhibitor encoding sequence can be administered to the cells of the lung, including macrophages, in the form of an aerosol. The inhibitor 15 or inhibitor encoding sequence can be present in the aerosol as a particle (e.g. liposome, or non-infectious bacteria, for example, Listeria, in the case of the encoding sequence) that is phagocytosed by the pulmonary macrophages. Phagocytosis results in the 20 introduction into the macrophages of the inhibitor or inhibitor encoding sequence. Viral vectors can also be used to introduce the peptide inhibitor encoding sequence of the invention into cells of the pulmonary tree. The vectors can be introduced as an aerosol and 25 can take the form of a replication defective herpes or adenoviral vector. Retroviral vectors can also be used. (See, generally, Bajocchi et al, Nat. Genet. 3:229 (1993); Lemarchand et al, Circ. Res., 72:1132 (1993); Ram et al, Cancer Res. 53:83 (1993); Crystal, 30 Am. J. Med. 92:445 (1992); Yoshimura et al, Nucl. Acids

Res. 20:3233 (1992); Morecki et al, Cancer Immunol. Immunother. 32:342 (1991); Culver et al, Hum. Gene Ther. 1:399 (1990); Culver et al, Transplant. Proc., 23:170 (1991).)

5 Blood monocytes can be transformed (infected) *ex vivo* with the peptide inhibitor encoding sequence of the invention and then reintroduced into the patient so that the inhibitor is produced *in vivo*.

10 An alternative approach to inhibiting phosphorylation involves the use of ribozymes that recognize RNA sequences specifying Fc receptor phosphorylation sites (eg, in Fc $\gamma$ RIIA and/or in the  $\gamma$  subunit of Fc $\gamma$ RIIIA), as well as RNA sequences specifying enzyme active sites. Introduction of the 15 ribozyme can be effected using a carrier such as a liposome coated with IgG so as to direct insertion to Fc $\gamma$  receptor bearing cells. Alternatively, IgE-coated liposomes can be used to direct the ribozyme to mast cells or basophiles, or cells of that lineage, bearing 20 the IgE receptor Fc $\epsilon$ RI with its associated  $\gamma$  subunit. One skilled in the art will appreciate that this is an approach suitable for use in treating allergic 25 disorders. The  $\gamma$  subunit of the IgE receptor is responsible for transmitting the signal inducing the release of intracellular mediators by mast cells. The destruction of the  $\gamma$  chain RNA is predicted to inhibit the release of these bioactive products.

30 In accordance with the above approach, ribozymes administered as described would bind to a few selected sequences (eg, RNA splicing and 5' untranslated

sequences for which they were specific, for example, in Fc $\gamma$ RIIA RNA or Fc $\gamma$ RIIIA  $\gamma$  chain RNA) and the enzymatic activity associated with the ribozyme would result in digestion and thus removal of the RNA specifying 5 functional sequences of the receptor necessary for phagocytic signal transduction. For mast cells, RNA sequences specifying the sequences of the  $\gamma$  chain of Fc $\epsilon$ RI necessary for mediator release (eg, histamine, cytokines and leukotrienes) can be eliminated using 10 this strategy.

Where advantageous, continuous *in vivo* production of the ribozyme can be effected using *ex vivo* constructed packaging cells (eg, Psi2-like cells; see Miller and Rosman, *Biotechniques* 7:980, 1989 and 15 Current Protocols in Molecular Biology III:9.1, 1992 (Supp. 17)). One skilled in the art will appreciate that a suicide gene can be included in such a cell so that ribozyme production can be terminated.

A further approach to inhibiting receptor 20 phosphorylation involves the use of an antisense construct or ribozyme that targets Syk encoding sequences. The Syk gene product, but not the gene product of ZAP-70 of the Syk kinase family, has been shown to stimulate Fc $\gamma$ RI and Fc $\gamma$ RIIIA phagocytosis 25 mediated by both the  $\gamma$  and  $\xi$  chains. Thus, by targeting Syk sequences, inhibition of Syk dependent phosphorylation can be effected. Constructs and ribozymes suitable for use in this method can be readily selected by one skilled in the art (see Yagi et

al, Biochem. Biophys. Res. Comm. 200:28 (1994) for Syk gene sequence).

Soluble Fc Receptors:

In a further embodiment, the present invention relates to a method of inhibiting the interaction between immune complexes (eg, IgG-containing immune complexes) and membrane-associated Fc receptors and thereby suppressing the clearance of such complexes by phagocytosis (alternatively, the signalling through the Fc receptor resulting in the release of intracellular mediators). The method involves introducing into the circulation a soluble form of the Fc receptor that competes with the membrane bound form for immune complex binding. Transcripts of certain soluble forms have been identified in cells of megakaryocytic and monocyte/myeloid lineages (Rappaport et al, Exp. Hemotol. 21:589 (1993); Warmerdam et al, J. Exp. Med. 172:19 (1990)). These transcripts lack sequences coding for the transmembrane receptor region but retain sequences coding for the cytoplasmic domain. The present invention contemplates the production and use of soluble Fc receptors that include an extracellular domain alone or in combination with a cytoplasmic domain. Suitable receptors are capable of competing with membrane bound Fc receptors for binding of IgG-coated cells.

Soluble receptors of the invention can take the form of Fc $\gamma$ RI, Fc $\gamma$ RII or Fc $\gamma$ RIII extracellular domains

alone or binding portions thereof (alternatively, a soluble receptor of Fc $\epsilon$ RI can be employed taking the form of an extracellular domain alone or binding portion thereof). As noted above, cytoplasmic domains, 5 or portions thereof, can also be present. The following are examples of possible soluble receptors where the "I" and "IIA" correspond to Fc $\gamma$ RI and Fc $\gamma$ RIIA, respectively, and where  $\alpha$  and  $\gamma$  correspond to the  $\alpha$  and  $\gamma$  chains of Fc $\gamma$ RIII, the first designation 10 indicating the source of the extracellular domain and the second the source of the cytoplasmic domain: I:I, I, IIA, IIA:IIA, I:IIA,  $\alpha:\gamma$ ,  $\alpha$ ,  $\alpha$ :IIA, I: $\gamma$ .

15 Soluble receptors, depending on their nature, can be prepared chemically or recombinantly (Horton et al, Biotechniques 8:528 (1990)). The soluble receptors can be administered systemically or to the lung as described above in connection with inhibitors of receptor phosphorylation. When *in vivo* synthesis of 20 soluble receptors from sequences encoding same is to be effected, such sequences are inserted into appropriate vectors (see above) and operably linked to regulatory sequences functional in the target cell.

Fc Receptor Antisense Constructs:

25 In a further embodiment, the present invention relates to a method of inhibiting Fc receptor expression in mammalian host cells by introducing into such cells an antisense construct comprising, in the 5'-3' direction of transcription: i) a promoter

functional in the cells, ii) a segment of double-stranded DNA, the transcribed strand of which includes a sequence complementary to the endogenous mRNA of the Fc receptor the expression of which is to be inhibited, 5 and iii) a termination sequence functional in the host cells. This embodiment of the invention makes it possible to regulate the expression of a specific Fc receptor in cells producing multiple receptor classes. This specificity can be achieved by selecting for 10 inclusion in the DNA segment ((ii) above) sequences unique to the mRNA of the endogenous Fc receptor.

The sequence complementary to the endogenous Fc receptor mRNA is at least 15 nucleotides in length, preferably, at least 30 and, most preferably, at least 15 50. The sequence is typically less than 5000 nucleotides in length, preferably less than 2000, and most preferably less than 1000. The sequence can be complementary to a translated or untranslated region of the mRNA (see, for example, McKenzie et al, Molec. 20 Immunol. 29:1165 (1992)). Both the length of the antisense sequence and the mRNA site to which it binds can vary depending on the nature of the antisense sequence, the mRNA site and the degree of inhibition sought. Optimization of these parameters can be 25 effected without undue experimentation.

Appropriate regulatory sequences and vectors can be selected from those known in the art. Administration of the antisense construct, for example, to the lung and to the spleen, can be carried out as 30 described above using both *in vivo* and *ex vivo*

transformation protocols. One skilled in the art will appreciate that the antisense transcript itself can be introduced directly into the target cells using methods known in the art, including those described above.

5 In addition to the above approaches for inhibiting phagocytosis, the present invention also relates to a method of effecting inhibition by introducing into a cell having phagocytic potential Fc $\gamma$ RIIB (eg Fc $\gamma$ RIIB2), which is capable of inhibiting the function of Fc $\gamma$  receptors, including Fc $\gamma$ RIIA. Introduction of Fc $\gamma$ RIIB can be effected by transfecting/transforming a target cell with a construct comprising a sequence encoding Fc $\gamma$ RIIB, or portion thereof that effects the inhibition (Brooks et al, J. Exp. Med. 170:1369 (1989); Indik et 10 al, Blood 83:2072 (1994)). Suitable constructs can be 15 selected by one skilled in the art.

The following non-limiting Examples describe certain aspects of the invention in greater detail.

#### EXAMPLE I

##### 20 Production of Recombinant Soluble Fc $\gamma$ RIII

Recombinant soluble Fc $\gamma$ RIII proteins can be produced using expression vectors as described below. The soluble protein can correspond to Fc $\gamma$ RIII with the transmembrane domain removed. The constructs can be 25 introduced into mammalian cells under conditions such that expression of the receptor encoding sequence occurs. The recombinant proteins thus produced are

isolated both from the cell lysates and from the supernatants.

Transfection of adherent cells or cells in suspension:

5 Transfection of adherent cells, eg, CHO cells or COS cells, or an appropriate suspension cell system will be performed. Permanent transfectants expressing soluble forms of Fc $\gamma$  receptor will be established by electroporation, calcium phosphate or other established methods. Transfected cells will be allowed to grow 48 hours and selected in media containing Geneticin at 2 mg/ml (Gibco BRL, Gaithersburg, Maryland) or other selection drug. After approximately twelve weeks, positive colonies will be isolated and expanded for further characterization of the clones. The isolated 10 clones will be examined by enzyme-linked immunoassay (ELISA) using ELISA plates (Dynatech, Alexandria, Virginia) to select a transfectant cell line expression the highest quantity of the soluble receptor. Mass culture of adherent transfectants will be achieved by 15 employing the hollow-fiber tissue culture system.

20

EXAMPLE II

Function of Soluble Fc $\gamma$ RIII

25 The functions of soluble Fc $\gamma$ RIII proteins are assessed both *in vitro* and *in vivo*. The effect of soluble Fc receptors on IgG-immune complex binding to cellular membrane-bound receptors depends on several

5 factors including the local concentrations of the ligand and soluble receptor, the surface density of the membrane-bound receptor, the valence of the ligand and the relative affinities of the two receptor forms for ligand. The limiting factors in the interaction of soluble Fc $\gamma$ RIII receptors with ligand and cellular membranes can be deciphered using available model systems.

10 The *in vitro* assay systems rely on the competition of soluble receptors with cell membrane receptors for labeled IgG ligand and IgG-coated erythrocytes (EA). Fc $\gamma$  receptor-negative cells are transfected with transmembrane Fc $\gamma$ RIII molecules that retain the functional capacity to bind and ingest IgG-containing 15 immune complexes and antibody-coated cells (Ruiz and Schreiber, J. Clin. Invest. 88:149 (1991)). These assays are used to examine the function of soluble receptors and the ability of soluble receptors to interfere with membrane receptor detection of both EA 20 and oligomeric forms of IgG. The function of soluble Fc $\gamma$ RIII is also examined *in vivo*. In these studies, an established experimental animal model is used to study whether soluble Fc $\gamma$ RIII administered *in vivo* alters the clearance of antibody coated cells (Ruiz and Schreiber, 25 J. Clin. Invest. 88:149 (1991)). The immunoregulatory potential of soluble Fc $\gamma$ RIII is examined in this manner.

EXAMPLE III

Cytoplasmic Tyrosine Residues  
Required For Phagocytic Signal Mediation

Experimental Protocols:

5       *Plasmid construction and introduction of point mutations:*

The pSVL eucaryotic expression vector (Pharmacia LKB, Piscataway, NJ) was employed for expression of Fc $\gamma$ RIIIA in COS-1 cells. huFc $\gamma$ RIIIA  $\alpha$  cDNA was cloned into the 10 XbaI and BamHI cloning sites of pSVL. Similarly, muFc $\gamma$ RIIIA  $\gamma$  cDNA was cloned into XbaI and BamHI cloning sites. TCR/Fc $\gamma$ RIIIA  $\zeta$  was cloned into the XbaI and BamHI cloning sites of pSVL. Conservative 15 replacement of cytoplasmic tyrosines of the  $\gamma$  chain by phenylalanine was achieved using the two step overlap-extension polymerase chain reaction (PCR) (Horton et al, Biotechniques 8:528 (1990)). Double tyrosine substitution mutants were constructed sequentially by the substitution of the N-terminal tyrosine residue 20 followed by the substitution of the C-terminal tyrosine residue. Six clones from each mutant were isolated and subjected to DNA sequencing. Two clones from each tyrosine substitution were randomly selected for further studies from several clones with correct DNA 25 sequence.

*Transient transfection:*

Fc $\gamma$ RIIIA isoforms, Fc $\gamma$ RIIIA- $\gamma\gamma$ , Fc $\gamma$ RIIIA- $\zeta\zeta$ , were generated by cotransfection of COS-1 cells with cDNA of  $\gamma$  or  $\zeta$  as well as cDNA of  $\alpha$ . Transfections of cDNAs were carried out with a modified DEAE-Dextran method. Briefly, 300,000 COS-1 cells were seeded on 35 mm well plates 24 hours prior to transfection. Plates of 70 to 80 % confluence were washed twice and incubated for 30 minutes with Dulbecco's Modification of Eagle's Medium (DMEM, Gibco BRL, Grand Island, NY) before transfection. Four  $\mu$ g of plasmid DNA (0.5  $\mu$ g/ $\mu$ l) was slowly added to 1 ml of a transfection buffer containing Nu medium (DMEM with 10 % of NuSerum [Collaborative Biomedical, Two Oak Park, Bedford, MA], 1 mg/ml of DEAE Dextran and 100  $\mu$ M chloroquine. The transfection buffer containing DNA was added to COS-1 cells with incubation for 4 hours at 37°C. Cells were then shocked with 10% DMSO in phosphate buffered saline (PBS) for 2 minutes, washed twice with DMEM and grown in NuSerum supplemented DMEM. Cells were studied 48 hours following transfection.

*Immunofluorescence staining and flow cytofluorimetry:* Transfected cells were harvested with staining buffer (PBS containing 0.02 % sodium azide and 0.1% BSA) using transfer pipettes. Cells were centrifuged, resuspended in 60  $\mu$ l of staining buffer and incubated with either the anti-Fc $\gamma$ RIII mAb, 3G8 (Unkeless et al, Annu. Rev. Immunol. 6:251 (1988)), or an isotype control for 30 minutes at 4°C. Cells were

washed and stained with fluorescein-conjugated goat anti-mouse IgG (Tago Inc. Burlingame, CA). The stained cells were examined using a FACStar flowcytometer (Becton Dickinson Co., Mountain View, CA).

5       *Binding and phagocytosis of IgG-sensitized RBCs (EA):* Sterile sheep red blood cells ( $10^9$ /ml) in calcium and magnesium-free PBS were sensitized by incubation with an equal volume of a subagglutinating titer of rabbit anti-sheep RBC antibody (Cappel Laboratories, Cochranville, PA). The IgG-sensitized RBCs (EA) were washed twice with PBS and resuspended to a final concentration of  $10^9$ /ml for overlaying on transfected COS-1 cells. Cells were examined for rosetting (> 10 EA per COS-1 cell) and phagocytosis as described previously (Indik et al, J. Clin. Invest. 88:A66 (1991)). For the analysis of phagocytosis, COS-1 cells bound with EA (after three washings) were subjected to a brief hypotonic shock (35 seconds) with hypotonic PBS to remove surface bound EA. The cells were then stained with Wright-Giemsa staining solutions, and phagocytosis (ingested EA) was determined by light microscopy. Results obtained were analyzed by Student's T-test.

20       *In vitro kinase assay:*  
25       Transfected cells ( $2 \times 10^7$  cells) were washed once with PBS and incubated sequentially on ice with 5  $\mu$ g/ml each of anti-Fc $\gamma$ RIII mAb and goat anti-mouse IgG for 10 minutes. Cells were washed once with PBS and incubated

at room temperature for 3 minutes before adding 1.5 ml of lysis buffer (150 mM NaCl, 25 mM Hepes [pH 7.4] and 1% polyoxyethylene 10 oleyl ether [BRIJ-96; Sigma, St. Louis, MO]) containing phosphatase and protease 5 inhibitors. Inhibitors of phosphatases and proteases (1mM EGTA, 1 mM Na orthovanadate, 1 mM PMSF, 10  $\mu$ g/ml aprotinin, 50  $\mu$ g/ml leupeptin, and 100  $\mu$ g/ml soybean trypsin inhibitor) were added fresh to lysis buffer. After 15 minutes of lysis on ice, cell lysates were 10 centrifuged for 30 minutes at 4°C to clarify. The Fc $\gamma$ RIIIA- $\gamma$  chain was immunoprecipitated with anti-human  $\gamma$  antiserum (provided by Jean-Pierre Kinet, NIAID-NIH, Rockville, MD) and Protein A-sepharose CL4B (Sigma, St. Louis, MO) in lysis buffer. Pellets were washed three 15 times in lysis buffer and once in low salt buffer (100 mM NaCl, 25 mM Hepes, pH 7.4 and 5 mM MnCl<sub>2</sub>). Pellets were incubated (20°C, 10 min.) with 30  $\mu$ l of a mixture containing 25 mM Hepes, pH 7.4, 5 mM MnCl<sub>2</sub>, 5 mM p-nitrophenyl-phosphate, 1  $\mu$ M cold ATP (Boehringer 20 Mannheim, Indianapolis, IN) and 5  $\mu$ Ci $\gamma$ -[<sup>32</sup>P]ATP (6000 Ci or 222 TBq/mmol; Dupont NEN, Boston, MA). Reactions were stopped by adding reducing SDS-PAGE sample buffer and labelled proteins were separated on a 12.5% reducing SDS-PAGE gel. The gel was fixed in 25 methanol/acetic acid, treated with 1 N KOH (2 hrs at 55°C) to remove phosphoserine and threonine, dried and autoradiographed for 4 days.

$[Ca^{2+}]_i$  Mobilization:

COS-1 cells plated on glass coverslips were incubated with 2  $\mu$ M Fura-2/AM (Calbiochem. San Diego, CA) for 30 minutes, washed twice and the coverslips then 5 transferred to a Leidem cell chamber (Medical Systems, Greenville, NY) for multiple single-cell measurements of  $[Ca^{2+}]_i$ . Fc $\gamma$ RIIIA receptors were crosslinked either with biotinylated anti-Fc $\gamma$ RIII followed by the addition of streptavidin or with anti-Fc $\gamma$ RIII mAB 3G8 whole IgG. 10 As a positive control, 10  $\mu$ M epinephrine was added to crosslink epinephrine receptors expressed on COS cells. Calcium imaging was performed using a 40x fluorescence objective on a Nikon Diaphot microscope with the image-1 AT quantitative fluorescence system (Universal 15 Imaging, West Chester, PA). Images were acquired at either 340 or 380 nm excitation (emission = 510 nm). 340/380 ratio images were calculated on a pixel by pixel basis and the average 340/380 ratio within each cell determined at each time point. 340/380 ratios 20 were converted to  $[Ca^{2+}]_i$  based on solution calibration using free Fura-2 acid.

Phagocytosis Mediated by Fc $\gamma$ RIIIA  $\alpha$  and Associated  $\gamma$  and  $\zeta$  Chains:

Wild type  $\gamma$  and  $\zeta$  cDNAs of Fc $\gamma$ RIIIA were 25 cotransfected with the Fc $\gamma$ RIIIA- $\alpha$  chain into COS-1 cells to examine their ability to induce phagocytosis of EA (sensitized RBC). Surface expression of Fc $\gamma$ RIIIA was determined by flow cytometry and was equally

efficient in cotransfection with either  $\gamma$  or  $\zeta$  (Table 1). The mean fluorescence intensity (FMI) for cotransfected cells stained with anti-Fc $\gamma$ RIII mAB increased by 15 fold compared to cells stained with an IgG isotype control or compared to mock-transfected cells stained with anti-Fc $\gamma$ RIII mAB (Table 1). The transfectants were examined for their ability to bind and phagocytose IgG sensitized RBCs (EA). Approximately 50% of COS-1 transfectants avidly bound EA (Table 1). Microscopic examination of COS-1 cells transfected with wild type  $\gamma$  consistently showed the ingestion of EA by 20 $\pm$ 5 % of the cells examined (p<0.02). Thus, phagocytosis of EA was detected in approximately 40% of COS-1 cell transfectants that bound EA. In contrast, cotransfectants containing the  $\zeta$  chain revealed 3.8% of cells with ingested EA (p<0.02) (Table 1). Moreover, in  $\zeta$ -containing cells which demonstrated phagocytosis the average number of ingested EA per cell was reduced to less than one half the level of that observed with  $\gamma$ . COS-1 cells transfected with all three cDNAs,  $\alpha$ ,  $\gamma$ , and  $\zeta$ , revealed 16% cells with ingested EA, showing consistent attenuation in phagocytosis (Table 1). In contrast, neither sham transfectants with EA nor transfectants with E (non-sensitized RBC) exhibited any binding or phagocytosis.

**TABLE 1. Fc $\gamma$ RIIIA expression and Phagocytosis by COS-1 Cells Transfected with Fc $\gamma$ RIIIA ( $\gamma$  and/or  $\zeta$ ).**

<u>Fc<math>\gamma</math>RIIIA</u>	<u>MFI*</u>	<u>PI<math>\ddagger</math></u>	<u>Phagocytosis (% Cells +)</u>	<u>Rosetting (% Cells +)</u>
$\alpha$ + pSVL (Sham)	15	0	0	0
$\alpha$ + $\gamma$	254	129 $\pm$ 21.0	20 $\pm$ 5.0	48 $\pm$ 3.0
$\alpha$ + $\zeta$	220	19 $\pm$ 3.2	3.8 $\pm$ 0.7	50 $\pm$ 1.7
$\alpha$ + $\zeta$ + $\gamma$	205	77 $\pm$ 5.0	16 $\pm$ 3.2	46 $\pm$ 2.0

Transfection efficiency was determined by flow cytometry. The mean fluorescence intensity (MFI) is shown for one of 3 separate experiments with similar results. Internalized RBCs were microscopically scored (1000 $\times$ ). Results are expressed as the mean  $\pm$  SEM for phagocytosis and binding (rosetting) of EA. At least 3 separate experiments were performed for each clone. For each experiment, 1500 cells were counted at 5 randomly selected sites. \* Mean Fluorescence Intensity.  $\ddagger$  PI (Phagocytic Index): number of RBCs internalized per 100 COS-1 cells

Two Cytoplasmic Tyrosines of the  $\gamma$  Chain are Required for Phagocytosis:

To study the effect of the two conserved  $\gamma$  chain tyrosines on Fc $\gamma$ RIIIA mediated phagocytosis, the N-  
5 proximal (clones M1A and M1B) or C-proximal (clones M2A and M2B) tyrosines were individually replaced by phenylalanine. For mutants with double tyrosine substitutions, both tyrosines were replaced by phenylalanine (DMA and DMB) (Fig. 1).

10 MFI measured by flow cytofluorimetry and % of positive cells with rosetting demonstrated similar surface expression of the receptor complexes in all transfectants bearing  $\gamma$  mutants and wild type  $\gamma$  (Table 2). These comparable levels of expression indicate  
15 that tyrosine residues in the cytoplasmic tail of the  $\gamma$  chain are not necessary for formation of the Fc $\gamma$ RIIIA receptor complex required for surface expression. Results summarized in Table 2 are as follows: M1  $\gamma$  mutants showed more than 99% reduction in phagocytic  
20 activity as shown by phagocytic index (PI) ( $\leq 1\%$  of transfectants with ingested EA and minimal ingested EA per phagocytosing cell) ( $p < 0.02$ ); M2 and DM  $\gamma$  mutants demonstrated essentially no phagocytosis (1 among 5000 cells examined) (Table 2, Fig. 2).

**TABLE 2. *Fc $\gamma$ RIIA expression and Phagocytosis by COS-1 Cells Transfected with *Fc $\gamma$ RIIA - $\alpha\gamma$  (wild type or mutants).****

<u>Fc<math>\gamma</math>RIIA</u>	<u>MFI*</u>	<u>PI<math>\pm</math></u>	<u>Phagocytosis (% Cells +)</u>	<u>Rosetting (% Cells +)</u>
$\alpha + pSVL$ (Sham)	15	0	0	0
$\alpha + \gamma$ (WT)	254	129 $\pm$ 21.0	20 $\pm$ 5.0	49 $\pm$ 3.0
$\alpha + \gamma$ (M1A)	259	0.3 $\pm$ 0.2	0.2 $\pm$ 0.1	49 $\pm$ 2.5
$\alpha + \gamma$ (M1B)	303	1.0 $\pm$ 1.0	1.0 $\pm$ 1.0	50 $\pm$ 1.5
$\alpha + \gamma$ (M2A)	232	$\leq$ 0.04	$\leq$ 0.02	49 $\pm$ 1.5
$\alpha + \gamma$ (M2B)	256	$\leq$ 0.02	$\leq$ 0.02	48 $\pm$ 3.0
$\alpha + \gamma$ (DMA)	222	$\leq$ 0.02	$\leq$ 0.02	48 $\pm$ 2.5
$\alpha + \gamma$ (DMB)	328	$\leq$ 0.02	$\leq$ 0.02	49 $\pm$ 2.0

See Table 1. for legend

Inhibition of Phagocytosis by Tyrophostin 23:

To investigate whether phagocytosis requires phosphorylation of tyrosine residues, COS-1 cells cotransfected with Fc $\gamma$ RIIIA- $\alpha$  and wild type  $\gamma$  were 5 incubated with increasing concentrations of tyrophostin 23 (tyr 23), an inhibitor of tyrosine kinases (Yaish et al, Science 242:933 (1988)). Tyr 23 decreased 10 phagocytosis in a dose dependent manner, with 50% inhibition at 25  $\mu$ M and complete inhibition at 200-400  $\mu$ M ( $p<0.01$ ) (Table 3). In contrast, tyr 23 did not 15 affect the binding of EA. Inhibition of phagocytosis was not associated with reduction in viability, since transfectants pretreated with tyr 23 (400  $\mu$ M) followed by washing had phagocytic activity partially (3 hr wash, Table 3) or completely (overnight wash, data not shown) restored.

TABLE 3. *The Effect of Tyrophostin 23 (Tyr 23) on Phagocytosis by COS-1 Cells Transfected with Fc $\gamma$ RIIIA- $\alpha/\gamma$*

<u>Tyr 23</u> <u>(Concentration)</u>	<u>PI*</u>	<u>Rosetting</u> <u>(% Cells)</u>
0 $\mu$ M	125 $\pm$ 24	49 $\pm$ 3
25 $\mu$ M	68 $\pm$ 4	52 $\pm$ 9
50 $\mu$ M	26 $\pm$ 7	52 $\pm$ 8
100 $\mu$ M	16 $\pm$ 6	49 $\pm$ 7
200 $\mu$ M	1.2 $\pm$ 1	47 $\pm$ 5
400 $\mu$ M	0	48 $\pm$ 3
400 $\mu$ M + washing	63 $\pm$ 7	44 $\pm$ 6

\*PI. Phagocytic Index

Tyrosine Residues of the  $\gamma$  Subunit are Phosphorylated  
In Vitro:

The possibility that tyrosine residues of the  $\zeta$  chain are phosphorylated was examined by *in vitro* kinase assays using COS-1 transfectants. Results shown in Fig. 4 demonstrate that the tyrosine residues of the wild type  $\gamma$  chains are phosphorylated *in vitro*. In contrast, the mutant  $\gamma$  chain transfectants and the sham transfectants showed no detectable phosphorylation.

5 Since the single tyrosine substitution mutants (M1A and M2A) did not exhibit phosphorylation on the remaining tyrosine residues, it is likely that phosphorylation of either one of the two tyrosine residues requires the other tyrosine residue to be intact (Fig. 3). These

10 15 Since the single tyrosine substitution mutants (M1A and M2A) did not exhibit phosphorylation on the remaining tyrosine residues, it is likely that phosphorylation of either one of the two tyrosine residues requires the other tyrosine residue to be intact (Fig. 3). These phosphorylation data correlate well with the ability of the  $\gamma$  chain to induce a phagocytic signal, as substitution of either one of the tyrosine residues largely eliminates phagocytosis (Table 2, Fig. 2).

The *in vitro* kinase assay demonstrated a distinct band of approximately 40 kDa present in all lanes except the sham transfectants. This band may represent an associated phosphoprotein coprecipitating with  $\gamma$ .

Cytoplasmic Tyrosines of  $\gamma$  are Required for  
Mobilization of  $\text{Ca}^{2+}$ :

25 To examine whether the  $\gamma$  chain tyrosines are required for calcium mobilization, the calcium response following Fc $\gamma$ RIIA crosslinking was measured in

individual transfected cells (WT, M1A, M2A or DMA) using digital video microscopy (Fig. 4). Epinephrine, which evokes a  $\text{Ca}^{2+}$  signal in COS cells, was used as a positive control in all experiments. Transfectants with the WT receptor complex showed a typical transient calcium rise following cross-linking with biotinylated anti-Fc $\gamma$ RIII followed by the addition of streptavidin or with anti-Fc $\gamma$ RIII whole IgG. In 5 consecutive experiments (169 cells), 58% of cells responded to anti-Fc $\gamma$ RIII with a calcium signal at least 50% as large as than induced by 10  $\mu\text{M}$  epinephrine (Fig. 4, Table 4). In contrast, COS-1 cells transfected with either M1A, M2A or DMA showed markedly diminished calcium responses to anti-Fc $\gamma$ RIII, although in one of four experiments significant calcium mobilization was evoked in M1A transfected COS-1 cells.

**TABLE 4. The Effect of Tyrosine Substitutions on Calcium Mobilization Evoked by Cross-Linking of Fc $\gamma$ RIIIA**

<u>Fc<math>\gamma</math>RIII</u>	<u>No. of Experiments</u>	<u>No. of Cells</u>	<u>% of Cells Responding*</u>
$\alpha + \gamma$ (WT)	5	169	57.8
$\alpha + \gamma$ (M1A)	4	123	16.0
$\alpha + \gamma$ (M2A)	4	117	2.8
$\alpha + \gamma$ (DMA)	4	70	3.7

\* Cells were scored as responding if the calcium response was more than 50% of that observed with 10  $\mu$ M epinephrine

EXAMPLE IV

Macrophage Fc $\gamma$ RIII Signaling Induces  
Protein Tyrosine Kinase Activation

Specific tyrosine residues in the intracellular  
5 Fc $\gamma$ RIII $\gamma$  subunit have been identified as necessary for

signal transduction and subsequent effector functions, using NK cells and lymphocytes or fibroblasts transfected with chimeric or mutated receptors. (Darby et al, Blood 79:352A Nov. (1992)) Fc $\gamma$ RIII in its native state on pulmonary macrophage or cultured monocytes (M) was examined in order to study the physiologically relevant protein tyrosine kinases (PTK) and phosphotyrosine containing substrates during macrophage signal transduction. Within seconds after Fc $\gamma$ RIII crosslinking with Fab antibody, Western blot analysis revealed a characteristic pattern of phosphotyrosine substrates. This response was transient with most substrates peaking at 5 min. and declining after 10-20 min. Phosphotyrosine patterns were indistinguishable in fresh macrophage and cultured monocytes, validating the latter as a useful *in vitro* model. P62, a protein associated with p120<sup>ras</sup>GAP, although not GAP itself, was identified by specific immunoprecipitation as one of these phosphotyrosine substrates. A second substrate was found to be p95<sup>vav</sup>, a hematopoietic oncogene product which is also tyrosine phosphorylated after TCR, slg and Fc $\epsilon$ RI activation. The kinase PTK72/Syk, heretofore identified only in B cell slg and mast cell Fc $\epsilon$ RI signaling, was also a major phosphotyrosine substrate after macrophage Fc $\gamma$ RIII activation. *In vitro* kinase assays of anti-Syk immune complexes revealed a 3-4 fold increase in Syk autophosphorylation at 5-10 min. after receptor ligation. Syk has also been found to be present in

immunoprecipitates of the  $\gamma$  chain Fc $\gamma$ RIIIA suggesting that Syk is associated with phosphorylated  $\gamma$  chain.

\* \* \* \*

5 All documents cited above are incorporated herein by reference.

10 While the invention has been described in connection with what is presently considered to be the most practical and preferred embodiment, it is to be understood that the invention is not to be limited to the disclosed embodiment, but on the contrary, is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.

WHAT IS CLAIMED IS:

1. A method of preventing phagocytosis of immune complexes in a mammal comprising introducing into phagocytic cells of said mammal that are in contact with said immune complexes an inhibitor of a kinase endogenous to said cells that activates an Fc receptor present at the membrane of said cells, said introduction being effected under conditions such that the phagocytic potential of said cells is inhibited.
2. The method according to claim 1 wherein said immune complexes are IgG-containing immune complexes.
3. The method according to claim 1 wherein said inhibitor is a peptide or mimetic.
4. The method according to claim 3 wherein said peptide is introduced directly into said cells.
5. The method according to claim 3 wherein said peptide is incorporated into a liposome prior to introduction into said cells.
6. The method according to claim 3 wherein a DNA sequence encoding said peptide is introduced into said cells under conditions such that said DNA sequence is expressed and said peptide thereby produced.

7. The method according to claim 3 wherein said peptide comprises a sequence corresponding to the tyrosine-containing motif of the cytoplasmic domain Fc $\gamma$ RIIA or the  $\gamma$  chain of Fc $\gamma$ RIIIA or of Fc $\epsilon$ RI.

8. The method according to claim 3 wherein said peptide comprises the sequence Y-X2-L wherein X2 is any two amino acids.

9. The method according to claim 8 wherein X2 represents the amino acids of a Y-X2-L sequence of the cytoplasmic domain of Fc $\gamma$ RIIA or the  $\gamma$  chain of Fc $\gamma$ RIIIA or of Fc $\epsilon$ RI.

10. A method of preventing the clearance of immune complexes from a mammal comprising introducing into phagocytic cells of said mammal that are in contact with said immune complexes a molecule that specifically degrades transcripts encoding Fc receptors present at the membrane of said cells.

11. The method according to claim 10 wherein said immune complexes are IgG-containing immune complexes.

12. The method according to claim 10 wherein said molecule is a ribozyme.

13. A method of inhibiting the binding of immune complexes present in a mammal to membrane-bound Fc receptors comprising introducing into said mammal a

soluble Fc receptor that competes with said membrane-bound Fc receptor for binding to said immune complexes, wherein said introduction is effected under conditions such that binding of said immune complexes to said membrane-bound Fc receptor is inhibited.

14. The method according to claim 13 wherein said immune complexes are IgG-containing immune complexes.

15. The method according to claim 13 wherein said soluble Fc receptor consists essentially of the extracellular domain of an Fc $\gamma$  receptor, or binding portion thereof.

16. The method according to claim 13 wherein said soluble Fc receptor comprises an extracellular domain from a first Fc $\gamma$  receptor type or an Fc $\epsilon$  receptor type and a cytoplasmic domain from a second Fc $\gamma$  receptor type wherein at least one of said first and second receptor types is Fc $\gamma$ RI or the  $\alpha$  or  $\gamma$  chain of Fc $\gamma$ RIII.

17. A method of inhibiting the phagocytic potential of a mammalian cell expressing an Fc receptor comprising introducing into said cell a construct comprising, in the 5'-3' direction of transcription:

- i) a promoter functional in said cell,
- ii) a segment of double-stranded DNA the transcribed strand of which comprises a sequence

complementary to endogenous mRNA encoding said Fc receptor, and

iii) a termination sequence functional in said cell,

wherein said construct is introduced under conditions such that said complementary strand is transcribed and binds to said endogenous mRNA thereby reducing expression of said Fc receptor and inhibiting the phagocytic potential of said cell.

18. The method according to claim 17 wherein said sequence complementary to endogenous mRNA is complementary to an untranslated region of said mRNA.

19. A method of inhibiting the phagocytic potential of a mammalian cell expressing an Fc receptor comprising introducing into said cell a nucleic acid complementary to an endogenous mRNA encoding said Fc receptor, wherein said nucleic acid is introduced under conditions such that said nucleic acid binds to said mRNA and thereby inhibits translation of said mRNA into said Fc receptor.

20. The method according to claim 19 wherein said nucleic acid is an RNA molecule.

21. The method according to claim 19 wherein said nucleic acid is complementary to an untranslated region of said mRNA.

22. A method of inhibiting the signal transduction of the  $\gamma$  subunit of the mast cell IgE receptor Fc $\epsilon$ RI comprising introducing into mast cells bearing said receptor an inhibitor of a kinase endogenous to said cells that activates said signal transduction of said Fc $\epsilon$ RI receptor or the  $\gamma$  subunit thereof, said introduction being effected under conditions such that said signal transduction is inhibited.

23. The method according to claim 22 wherein said inhibitor is a peptide or mimetic.

24. The method according to claim 23 wherein said peptide comprises the sequence Y-X2-L, wherein X2 represents any two amino acid.

25. The method according to claim 24 wherein X2 represents the amino acids of a Y-X2-L sequence of the cytoplasmic domain of the  $\gamma$  chain Fc $\epsilon$ RI.

26. A construct comprising, in the 5'-3' direction of transcription:

- i) a promoter,
- ii) a segment of double-stranded DNA the transcribed stand of which comprises a sequence complementary to Fc receptor mRNA, and
- iii) a termination sequence,  
wherein said promoter, double-stranded DNA and termination sequence are operably linked.

27. A cell comprising said construct according to claim 26, wherein said promoter and said termination sequence are functional in said cell.

28. A soluble Fc receptor consisting essentially of the extracellular domain of an Fc $\gamma$  or Fc $\epsilon$  receptor, or binding portion thereof.

29. A soluble Fc $\gamma$  receptor comprising an extracellular domain from a first Fc $\gamma$  receptor type and a cytoplasmic domain from a second Fc $\gamma$  receptor type, wherein at least one of said first and second receptor types is Fc $\gamma$ RI or the  $\alpha$  or  $\gamma$  chain of Fc $\gamma$ RIII.

30. A DNA molecule encoding the soluble receptor of claim 28.

31. A DNA molecule encoding the soluble receptor of claim 29.

32. A peptide consisting essentially of the tyrosine-containing motif of the cytoplasmic domain of Fc $\gamma$ RIIA or the  $\gamma$  chain of Fc $\gamma$ RIIIA or Fc $\epsilon$ RI, or functional portion thereof.

33. A DNA molecule encoding the peptide of claim 32.

34. A cell comprising the peptide according to claim 32.


35. A peptide that inhibits phagocytosis, or mediator release from mast cells, comprising a portion of the cytoplasmic domain of Fc $\gamma$ RII or of the  $\gamma$  chain of Fc $\gamma$ RIIIA or of Fc $\epsilon$ RI that is free of the sequence Y-X2-L, wherein X2 represents the two amino acids of the Y-X2-L sequence of the cytoplasmic domain of Fc $\gamma$ RII or the  $\gamma$  chain of Fc $\gamma$ RIIIA or of Fc $\epsilon$ RI.

36. The method according to claim 1 wherein said inhibition reduces or prevents regional tissue damage resulting from monocyte or neutrophil activation.

37. A method of inhibiting the phagocytic potential of a Syk-producing cell comprising introducing into said cell an antisense construct or ribozyme that targets Syk encoding sequences present in said cell under conditions such that production of Syk is inhibited.


38. A method of inhibiting the phagocytic potential of a cell comprising introducing into said cell Fc $\gamma$ RIIB under conditions such that said inhibition is effected.

1 / 8

**FIG. 1**

SUBSTITUTE SHEET (RULE 26)

2 / 8




**FIG. 2A**



**FIG. 2B**

SUBSTITUTE SHEET (RULE 26)

3 / 8




**FIG. 2C**




**FIG. 2D**

SUBSTITUTE SHEET (RULE 26)

4 / 8




**FIG. 2E**




**FIG. 2F**

5 / 8




**FIG. 2G**



**FIG. 2H**



SUBSTITUTE SHEET (RULE 26)

6 / 8

**FIG. 3**



SUBSTITUTE SHEET (RULE 26)

7 / 8

**FIG. 4A****FIG. 4B**

SUBSTITUTE SHEET (RULE 26)

8 / 8

**FIG. 4C****FIG. 4D**

SUBSTITUTE SHEET (RULE 26)

## INTERNATIONAL SEARCH REPORT

International application No.

US94/11108

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 38/00, 31/70, 48/00

US CL : 514/2, 44; 536/23.4, 23.5

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2, 44; 536/23.4, 23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, BIOSIS, Derwent World Patent Index

search terms: phagocyt?, fc, domain, kinase, syk, antisense, peptide, inhibit

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim N .
Y	The Journal of Biological Chemistry, Volume 268, No. 21, issued 25 July 1993, A. Agarwal et al., "Involvement of p72 <sup>syk</sup> , a Protein-Tyrosine Kinase, in Fc <sub>y</sub> Receptor Signaling", pages 15900-15905, see entire document.	1-38
Y	TIBTECH, Volume 8, issued July 1990, J. Rossi et al., "RNA Enzymes (Ribozymes) as Antiviral Therapeutic Agents", pages 179-183, see entire document.	10-12, 37
Y	Blood, Volume 77, No. 3, issued 01 February 1991, W. Akerley III et al., "Neutrophil Activation Through High-Affinity Fc <sub>y</sub> Receptor Using a Monomeric Antibody With Unique Properties", pages 607-615, see entire document.	13-16, 28

 Further documents are listed in the continuation of Box C.

See patent family annex.

• Special categories of cited documents:		
•A• document defining the general state of the art which is not considered to be of particular relevance	•T•	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
•E• earlier document published on or after the international filing date	•X•	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
•L• document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	•Y•	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
•O• document referring to an oral disclosure, use, exhibition or other means	•g•	document member of the same patent family
•P• document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

02 NOVEMBER 1994

Date of mailing of the international search report

12 JAN 1995

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

CHARLES C. P. RORIES, Ph.D.

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)★

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/11108

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Oncogene, Volume 1, issued 1987, O. Shohat et al., "Inhibition of Cell Growth Mediated by Plasmids Encoding p53 Anti-Sense", pages 277-283, see entire document.	17, 18, 26, 27, 37
Y	US, A, 5,087,617 (SMITH) 11 February 1992, columns 13-16.	19-21
Y	Journal of Immunology, Volume 150, No. 8, Part II, issued 15 April 1993, Z. Indik et al., "Examination of Phagocytosis by Chimeric Fc $\gamma$ Receptors", page 306A, abstract no. 1754, see entire abstract.	29, 31
Y	US, A, 5,189,014 (COWAN, JR.) 23 February 1993, columns 1-17.	1-38
Y	US, A, 4,686,282 (HAHN) 11 August 1987, columns 1-10.	1-38